RT Journal Article
T1 European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022.
A1 Garbe, Claus
A1 Amaral, Teresa
A1 Peris, Ketty
A1 Hauschild, Axel
A1 Arenberger, Petr
A1 Basset-Seguin, Nicole
A1 Bastholt, Lars
A1 Bataille, Veronique
A1 Del Marmol, Veronique
A1 Dréno, Brigitte
A1 Fargnoli, Maria C
A1 Forsea, Ana-Maria
A1 Grob, Jean-Jacques
A1 Höller, Christoph
A1 Kaufmann, Roland
A1 Kelleners-Smeets, Nicole
A1 Lallas, Aimilios
A1 Lebbé, Celeste
A1 Lytvynenko, Bohdan
A1 Malvehy, Josep
A1 Moreno-Ramirez, David
A1 Nathan, Paul
A1 Pellacani, Giovanni
A1 Saiag, Philippe
A1 Stratigos, Alexander J
A1 Van Akkooi, Alexander C J
A1 Vieira, Ricardo
A1 Zalaudek, Iris
A1 Lorigan, Paul
A1 European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC)
K1 AJCC classification
K1 Confocal reflectance microscopy
K1 Cutaneous melanoma
K1 Dermatoscopy
K1 Follow-up examinations
K1 Imaging diagnostics
K1 Mutation testing
K1 Primary diagnosis
K1 Sequential digital dermatoscopy
K1 Total body photography
AB Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed with dermatoscopy. If a melanoma is suspected, a histopathological examination is always required. Sequential digital dermatoscopy and full body photography can be used in high-risk patients to improve the detection of early melanoma. Where available, confocal reflectance microscopy can also improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the American Joint Committee on Cancer classification. Thin melanomas up to 0.8 mm tumor thickness do not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC onwards whole-body examinations with computed tomography (CT) or positron emission tomography CT (PET-CT) in combination with brain magnetic resonance imaging are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to define the frequency and extent of examinations. A stage-based follow-up scheme is proposed which, according to the experience of the guideline group, covers the optimal requirements, but further studies may be considered. This guideline is valid until the end of 2024.
YR 2022
FD 2022-05-12
LK http://hdl.handle.net/10668/22174
UL http://hdl.handle.net/10668/22174
LA en
DS RISalud
RD Apr 9, 2025